natgillin/translations-raw huggingface dataset:
Androgen deprivation therapies, such as treatment with LHRH analogues or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour.
Zdravljenje z androgeno deprivacijo, kot je zdravljenje z analogi gonadorelina (LHRH) ali z orhidektomijo, zmanjša nastajanje androgenov v modih, ne vpliva pa na nastajanje androgenov v nadledvičnih žlezah ali v tumorju.
If the patient is engaged in sex with a woman of childbearing potential, a condom is required along with another effective contraceptive method.
Če ima bolnik spolne odnose z žensko v rodni dobi, je treba poleg kondoma uporabljati še katero od drugih učinkovitih metod kontracepcije.
How to take ZYTIGA
Kako jemati zdravilo ZYTIGA
Janssen-Cilag B.V. Graaf Engelbertlaan 75 NL-4837 DS Breda Tel: +31 76 711 1111
Janssen-Cilag BV Graaf Engelbertlaan 75 NL-4837 DS Breda Tel: +31 76 711 1111
This finding is considered related to the pharmacological action of abiraterone and rat specific.
Ugotovitev povezujejo s specifičnim farmakološkim delovanjem abiraterona pri podganah.
Sixty-five percent (354 of 546) of patients treated with ZYTIGA, compared with 71% (387 of 542) of patients treated with placebo, had died.
Umrlo je 65% (354 od 546) bolnikov, ki so se zdravili z zdravilom ZYTIGA in 71% (387 od 542) bolnikov, ki so prejemali placebo.
This medicinal product should be prescribed by an appropriate healthcare professional.
To zdravilo lahko predpiše zdravnik specialist ustreznega področja.
Examples of medicinal products metabolised by CYP2D6 include metoprolol, propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone and tramadol (the latter three medicinal products requiring CYP2D6 to form their active analgesic metabolites).
Med zdravila, ki jih presnavlja CYP2D6, spadajo metoprolol, propranolol, dezipramin, venlafaksin, haloperidol, risperidon, propafenon, flekainid, kodein, oksikodon in tramadol (zadnje tri učinkovine se preko CYP2D6 pretvorijo v aktivne protibolečinske presnovke).
There have been rare post-marketing reports of acute liver failure and hepatitis fulminant, some with fatal outcome (see section 4.8).
V obdobju trženja zdravila so redko poročali o akutni odpovedi jeter in fulminantnem hepatitisu, v nakaterih primerih tudi s smrtnim izidom (glejte poglavje 4.8).
Co-administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive, resulting in a reduction in incidence and severity of these adverse reactions.
Sočasna uporaba kortikosteroidov zavira delovanje adenokortikotropnega hormona (ACTH), kar zmanjšuje pogostnost in izraženost navedenih neželenih učinkov.
Use with ZYTIGA is not recommended (see section 5.1).
Sočasna uporaba z zdravilom ZYTIGA ni priporočljiva (glejte poglavje 5.1).
If you plan to take Ra-223 following treatment with ZYTIGA and prednisone/prednisolone, you must wait 5 days before starting treatment with Ra-223.
Če nameravate vzeti Ra-223 po zaključku zdravljenja z zdravilom ZYTIGA, skupaj s prednizonom/prednizolonom, morate z uvedbo zdravljenje z Ra-223 počakati še 5 dni.
The median rPFS was 16.5 months in the abiraterone acetate group and 8.3 months in the placebo group.
Mediano rPFS je bilo v skupini, ki je prejemala abirateronacetat 16,5 mesecev in v skupini, ki je prejemala placebo 8,3 mesecev.
Based on this observed trend, the product information (SmPC Section 4.4) should be updated to reflect that rhabdomyolysis/myopathy may occur between 1 to 6 months after initiation of therapy with AA.
Na osnovi opaženega trenda je treba informacije o zdravilu (poglavje 4.4 povzetka glavnih značilnosti zdravila) posodobiti s podatki, da se lahko rabdomioliza/miopatija pojavita med 1. in 6. mesecem po uvedbi zdravljenja z AA.
In addition to the co-primary endpoint measures, benefit was also assessed using time to opiate use for cancer pain, time to initiation of cytotoxic chemotherapy, time to deterioration in ECOG performance score by ≥ 1 point and time to PSA progression based on Prostate Cancer Working Group-2 (PCWG2) criteria.
Poleg primarnih meril so za oceno koristi zdravljenja uporabili čas do uporabe opiatov za bolečino pri karcinomu, čas do uvedbe citotoksične kemoterapije, čas do poslabšanja stanja zmogljivosti do ≥ 1 po lestvici ECOG in čas do napredovanja koncentracij PSA po kriterijih Prostate Cancer Working Group2 (PCWG2).
In addition to the observed improvement in overall survival, all secondary study endpoints favoured ZYTIGA and were statistically significant after adjusting for multiple testing as follows:
Poleg opaženega izboljšanja celokupnega preživetja so vse primerjave pri sekundarnih ciljih opazovanja govorile v prid uporabe zdravila ZYTIGA, razlike pa so bile po prilagajanju na multipla testiranja statistično značilne, in sicer:
Each pack contains one bottle.
Eno pakiranje vsebuje eno plastenko.
Following oral administration of abiraterone acetate in the fasting state, the time to reach maximum plasma abiraterone concentration is approximately 2 hours.
Po peroralnem vnosu abirateronacetata na tešče doseže koncentracija abiraterona v plazmi najvišjo vrednost v približno 2 urah.
In studies of patients with metastatic advanced prostate cancer who were using an LHRH analogue, or were previously treated with orchiectomy, ZYTIGA was administered at a dose of 1,000 mg daily in combination with low dose prednisone or prednisolone (either 5 or 10 mg daily depending on the indication).
V študijah so bolnikom z napredovalim metastatskim rakom prostate, ki so prejemali enega od analogov LHRH ali so bili predhodno zdravljeni z orhidektomijo, dajali zdravilo ZYTIGA v odmerku 1.000 mg na dan v kombinaciji z majhnim odmerkom prednizona ali prednizolona (5 mg ali 10 mg na dan, odvisno od indikacije).
Re-treatment may take place only after return of liver function tests to the patient's baseline and at a reduced dose level (see section 4.2).
Zdravljenje je mogoče ponovno uvesti, šele ko se vrednosti testov jetrne funkcije vrnejo na bolnikove izhodiščne vrednosti, ter z nižjim odmerkom (glejte poglavje 4.2).
Patients with known brain metastasis, uncontrolled hypertension, significant heart disease, or NYHA Class IIIV heart failure were excluded.
Izključili so bolnike z znanimi možganskimi metastazami, nenadzorovano hipertenzijo, pomembnimi boleznimi srca ali srčnim popuščanjem razreda II do IV po klasifikaciji NYHA.
Women who are or may be pregnant should not handle ZYTIGA without gloves.
Ženske, ki so ali bi lahko bile noseče, morajo z zdravilom ZYTIGA rokovati v rokavicah.
ZYTIGA should be used with caution in patients with a history of cardiovascular disease.
Pri uporabi zdravila ZYTIGA pri bolnikih z anamnezo kardiovaskularne bolezni je potrebna previdnost.
Of 15 detectable metabolites, 2 main metabolites, abiraterone sulphate and N-oxide abiraterone sulphate, each represents approximately 43% of total radioactivity.
Izmed 15 presnovkov, ki jih je mogoče določati, dva glavna presnovka (abirateronsulfat in abirateronsulfat-N-oksid) prispevata večji del skupne radioaktivnosti, in sicer vsak približno 43% skupne radioaktivnosti.
Caution is recommended in patients concomitantly treated with medicinal products known to be associated with myopathy/rhabdomyolysis.
Pri bolnikih, ki se sočasno zdravijo z zdravili, za katera je znano, da so povezana z miopatijo/rabdomiolizo, je potrebna previdnost.
Time to degradation in the FACT-P (Total Score): Treatment with ZYTIGA decreased the risk of FACT-P (Total Score) degradation by 22% compared with placebo (p = 0.0028).
Čas do poslabšanja v FACT-P (skupna ocena): Zdravljenje z zdravilom ZYTIGA zmanjša tveganje za poslabšanje v FACT-P (skupna ocena) za 22% v primerjavi s placebom (p=0,0028).
The mean half-life of abiraterone is prolonged to approximately 18 hours in subjects with mild hepatic impairment and to approximately 19 hours in subjects with moderate hepatic impairment.
Povprečen razpolovni čas abiraterona je pri osebah z blago okvaro jeter podaljšan na približno 18 ur, pri osebah z zmerno okvaro jeter pa na približno 19 ur.
How much to take The recommended dose is 1,000 mg (two tablets) once a day.
Kako velik odmerek zdravila jemati Priporočeni odmerek je 1.000 mg (dve tableti) enkrat na dan.
Summary of the safety profile
Povzetek varnosti zdravila
How much to take The recommended dose is 1,000 mg (four tablets) once a day.
Kako velik odmerek zdravila jemati Priporočeni odmerek je 1.000 mg (štiri tablete) enkrat na dan.
In patients with pre-existing hypokalaemia or those that develop hypokalaemia whilst being treated with ZYTIGA, consider maintaining the patient's potassium level at ≥ 4.0 mM.
Pri bolnikih z obstoječo hipokaliemijo ali pri tistih, pri katerih je do hipokaliemije prišlo med zdravljenjem z zdravilom ZYTIGA, je treba razmisliti o vzdrževanju koncentracije kalija ≥ 4,0 mmol/l.
Objective response: Objective response was defined as the proportion of subjects with measurable disease achieving a complete or partial response according to RECIST criteria (baseline lymph node size was required to be ≥ 2 cm to be considered a target lesion).
Objektivni odgovor na zdravljenje: Objektivni odgovor na zdravljenje je bil definiran kot delež preiskovancev z znanimi boleznimi, ki so dosegli popolni ali delni odgovor na podlagi meril RECIST (izhodiščna mejna velikost bezgavke ≥ 2 cm).
Pain progression was defined as an increase from baseline of ≥ 30% in the BPI-SF worst pain intensity score over the previous 24 hours without a decrease in analgesic usage score observed at two consecutive visits, or an increase of ≥ 30% in analgesic usage score observed at two consecutive visits.
Napredovanje bolečine je bilo opredeljeno kot zvečanje za ≥ 30% od izhodiščne vrednosti ocene najhujše bolečine v zadnjih 24 urah po vprašalniku BPI-SF in brez znižanja ocene porabe analgetikov, kar so ocenjevali na dveh zaporednih obiskih, ali pa kot zvišanje za ≥ 30% ocene porabe analgetikov med dvema zaporednima obiskoma.
Hazard ratio <1 favors AA-P.
Razmerje tveganja  1 kaže prednost AA-P.
The proportion of patients with pain palliation was statistically significantly higher in the ZYTIGA group than in the placebo group (44% vs. 27%, p = 0.0002).
Delež bolnikov, ki so jim paliativno lajšali bolečino, je bil statistično značilno večji v skupini z zdravilom ZYTIGA kot v skupini s placebom (44% v primerjavi s 27%, p = 0,0002).
Blood monitoring
Krvni testi
The median time to progression was 26.7 months in the ZYTIGA group and 18.4 months in the placebo group.
Mediani čas do napredovanja je bil 26,7 meseca v skupini, ki je prejemala zdravilo ZYTIGA in 18,4 meseca v skupini, ki je prejemala placebo.
This medicinal product also contains more than 1.18 mmol (or 27 mg) sodium per dose of two tablets.
Zdravilo vsebuje tudi več kot 1,18 mmol (oziroma 27 mg) natrija na odmerek (v dveh tabletah).
The incidence of cardiovascular adverse reactions in the Phase 3 studies in patients taking abiraterone acetate versus patients taking placebo were as follows: atrial fibrillation 2.6% vs. 2.0%, tachycardia 1.9% vs. 1.0%, angina pectoris 1.7% vs. 0.8%, cardiac failure 0.7% vs. 0.2%, and arrhythmia 0.7% vs. 0.5%.
Incidenca kardiovaskularnih neželenih učinkov v študijah faze 3 pri bolnikih, ki so jemali abirateronacetat, v primerjavi z bolniki, ki so prejemali placebo, je takšna: atrijska fibrilacija 2,6% proti 2,0%, tahikardija 1,9% proti 1,0%, angina pektoris 1,7% proti 0,8%, srčno popuščanje 0,7% proti 0,2% in aritmija 0,7% proti 0,5%.
Cardiovascular reactions
Kardiovaskularni učinki
The number of patients treated with ZYTIGA by racial group was Caucasian 832 (69.4%), Asian 246 (20.5%), Black or African American 25 (2.1%), other 80 (6.7%), unknown/not reported 13 (1.1%), and American Indian or Alaska Native 3 (0.3%).
Število bolnikov, zdravljenih z zdravilom ZYTIGA glede na raso je bilo: 832 (69,4%) belcev, 246 (20,5%) Azijcev, 25 (2,1%) črncev ali afroameričanov, 80 (6,7%) bolnikov drugih ras, 13 (1,1%) neznanih/ni bilo poročano in 3 (0,3%) severnoameriški indijanci ali staroselci z Aljaske.
There are no data on the clinical safety and efficacy of multiple doses of abiraterone acetate when administered to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).
Podatkov o klinični varnosti in učinkovitosti večkratnih odmerkov abirateronacetata pri bolnikih z zmerno do hudo okvaro jeter (Child-Pugh razreda B ali C) ni.
Each 30 day carton contains 60 film-coated tablets in 5 cardboard wallets of 12 film-coated tablets each.
Eno 30 dnevno pakiranje vsebuje 60 filmsko obloženih tablet v 5 zloženkah po 12 filmsko obloženih tablet.
Taking this medicine - Take this medicine by mouth.
Jemanje zdravila - Zdravilo morate zaužiti.
Only patients with a baseline pain score of ≥ 4 and at least one post-baseline pain score were analysed (N = 512) for pain palliation.
Analizirali so samo podatke bolnikov z izhodiščno oceno bolečine ≥ 4, pri čemer so v analizo poleg izhodiščne vključili še najmanj eno poznejšo oceno bolečine (n=512) za presojo paliativnega zdravljenja.
Six hundred and seven (607) subjects had radiographic progression or died: 271 (50%) in the abiraterone acetate group and 336 (62%) in the placebo group.
Šeststosedem (607) preiskovancev je imelo radiološko potrjeno napredovanje bolezni ali umrlo: od tega jih je bilo 271 (50%) v skupini, ki je prejemala abirateronacetat in 336 (62%) v skupini, ki je prejemala placebo.
Each 28 day carton contains 56 film-coated tablets in 4 cardboard wallets of 14 film-coated tablets each.
Eno 28 dnevno pakiranje vsebuje 56 filmsko obloženih tablet v 4 zloženkah po 14 filmsko obloženih tablet.
For patients who develop hepatotoxicity during treatment, suspension of treatment and dose adjustment may be required (see sections 4.2 and 4.4).
Bolnikom, pri katerih pride med zdravljenjem do hepatotoksičnosti, je treba začasno prekiniti zdravljenje in prilagoditi odmerjanje (glejte poglavji 4.2 in 4.4).
Hypertension was reported in 36.7% of patients in the hormone sensitive population (study 3011) compared to 11.8% and 20.2% in studies 301 and 302, respectively.
V populaciji hormonsko občutljivih bolnikov (študija 3011) so o hipertenziji poročali pri 36,7% bolnikov v primerjavi z 11,8% bolnikov v študiji 301 in 20,2% bolnikov v študiji 302.
Caution is required in treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalaemia (e.g., those on cardiac glycosides), or fluid retention (e.g., those with heart failure, severe or unstable angina pectoris, recent myocardial infarction or ventricular arrhythmia and those with severe renal impairment).
Previdnost je potrebna pri zdravljenju bolnikov, pri katerih lahko osnovno bolezen poslabšajo zvišan krvni tlak, hipokaliemija (na primer bolniki, ki jemljejo kardiotonične glikozide) ali zastajanje tekočin (na primer bolniki s srčnim popuščanjem, hudo ali nestabilno angino pektoris, nedavnim miokardnim infarktom ali ventrikularno aritmijo in bolniki s hudo ledvično okvaro).
In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each decreased by 10% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate.
V študiji medsebojnega delovanja zdravil s CYP2C8 pri zdravih osebah se je AUC pioglitazona zvečala za 46% in AUC vsakega od aktivnih presnovkov pioglitazona, M-III in M-IV, pri jemanju skupaj z enkratnim 1.000 mg odmerkom abirateronacetata zmanjšala za 10%.
The pharmacokinetics of abiraterone acetate was compared in patients with end-stage renal disease on a stable haemodialysis schedule versus matched control subjects with normal renal function.
Farmakokinetične lastnosti abirateronacetata so primerjali med bolniki s končno odpovedjo ledvic, zdravljenih s stabilno dializno shemo, in med skladnimi kontrolnimi osebami z normalnim delovanjem ledvic.
Pain: Treatment with ZYTIGA significantly reduced the risk of average pain intensity progression by 18% compared with placebo (p = 0.0490).
Bolečina: Zdravljenje z zdravilom ZYTIGA pomembno zmanjša tveganje za napredovanje jakosti povprečne bolečine za 18% v skupini, ki je prejemala zdravilo ZYTIGA v primerjavi s placebom (p=0,0490).
Metabolism and nutrition disorders very common: hypokalaemia common: hypertriglyceridaemia
Presnovne in prehranske motnje zelo pogosti: hipokaliemija pogosti: hipertrigliceridemija
- Swallow the tablets whole with water.
- Tablete pogoltnite cele z vodo.
- This medicine may cause harm to the unborn child if it is taken by women who are pregnant.
- Če nosečnica jemlje zdravilo, lahko to škodi nerojenemu otroku .
ZYTIGA may cause hypertension, hypokalaemia and fluid retention as a pharmacodynamic consequence of its mechanism of action.
Hipertenzija, hipokaliemija in zastajanje tekočin, ki jih lahko povzroča zdravilo ZYTIGA, so farmakodinamične posledice mehanizma delovanja tega zdravila.
ZYTIGA decreases serum testosterone and other androgens to levels lower than those achieved by the use of LHRH analogues alone or by orchiectomy.
Zdravilo ZYTIGA znižuje koncentracije testosterona in drugih androgenov v serumu na vrednosti, ki so nižje kot pri samostojni uporabi analogov LHRH oziroma pri orhidektomiji.
The time to PSA progression was approximately doubled with ZYTIGA treatment (HR = 0.488).
Čas do zviševanja koncentracij PSA se je pri zdravljenju z zdravilom ZYTIGA približno podvojil (razmerje tveganja=0,488).
The recommended dose is 1,000 mg (four 250 mg tablets) as a single daily dose that must not be taken with food (see “Method of administration” below).
Priporočeni odmerek je 1.000 mg (štiri 250 mg tablete) v enem odmerku na dan, ki ga bolnik ne sme zaužiti skupaj s hrano (glejte “Način uporabe” v nadaljevanju).
- Take ZYTIGA at least two hours after eating and do not eat anything for at least one hour after taking ZYTIGA (see section 2, “ZYTIGA with food”).
- Zdravilo ZYTIGA jemljite najmanj dve uri po jedi, po zaužitju zdravila ZYTIGA pa najmanj eno uro ne uživajte nobene hrane (glejte poglavje 2 “Zdravilo ZYTIGA skupaj s hrano”).
Abnormal liver function tests developing in patients participating in clinical trials were vigorously managed by requiring treatment interruption and permitting re-treatment only after return of liver function tests to the patient's baseline (see section 4.2).
Na patološke vrednosti testov jetrne funkcije pri bolnikih v kliničnih študijah so se takoj odzvali s predpisano prekinitvijo zdravljenja, ponovna uvedba zdravila pa je bila dovoljena šele po znižanju testov jetrne funkcije na bolnikove izhodiščne vrednosti (glejte poglavje 4.2).
= confidence interval; ECOG = Eastern Cooperative Oncology Group performance score; HR = hazard ratio; NE = not evaluable
AA = zdravilo ZYTIGA; BPI (Brief Pain Inventory) = bolečinska lestvica; IZ = interval zaupanja; ECOG (Eastern Cooperative Oncology Group) = lestvica ocenjevanja stanja zmogljivosti; HR = razmerje tveganja (hazard ratio); NM = nemerljivo
Manufacturer Janssen-Cilag SpA Via C. Janssen Borgo San Michele I-04100 Latina, Italy
Via C. Janssen Borgo San Michele I-04100 Latina, Italija
The recommended dose is 1,000 mg (two 500 mg tablets) as a single daily dose that must not be taken with food (see “Method of administration” below).
Priporočeni odmerek je 1.000 mg (dve 500 mg tablete) v enem odmerku na dan, ki ga bolnik ne sme zaužiti skupaj s hrano (glejte “Način uporabe” v nadaljevanju).
What ZYTIGA looks like and contents of the pack - ZYTIGA tablets are white to off-white, oval shaped (15.9 mm long x 9.5 mm wide), with
Izgled zdravila ZYTIGA in vsebina pakiranja - Tablete ZYTIGA so bele do sivo bele barve in ovalne oblike (dolge 15,9 mm in široke 9,5 mm),
Across Phase 3 clinical studies, hepatotoxicity grades 3 and 4 (e.g., ALT or AST increases of > 5 x ULN or bilirubin increases > 1.5 x ULN) were reported in approximately 6% of patients who received abiraterone acetate, typically during the first 3 months after starting treatment.
Skupaj so v kliničnih študijah faze 3 o hepatotoksičnosti 3. in 4. stopnje (npr. zvišanje koncentracije ALT ali AST na > 5-kratnik zgornje meje normalnih vrednosti ali zvišanje koncentracije bilirubina na > 1,5-kratnik zgornje meje normalnih vrednosti) poročali pri približno 6% bolnikov, ki so prejemali abirateronacetat, večinoma v prvih 3 mesecih po začetku zdravljenja.
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rPFS).
Sočasni primarni cilji učinkovitosti so bili celokupno preživetje (OS-Overall Survival) in radiološko potrjeno preživetje brez napredovanja bolezni (rPFSradiographic Progression-Free Survival).
Patients were maintained on study treatments until there was PSA progression (confirmed 25% increase over the patient's baseline/nadir) together with protocol-defined radiographic progression and symptomatic or clinical progression.
Bolniki so prejemali študijsko zdravljenje dokler se je koncentracija PSA zviševala (potrjeno zvišanje za 25% od izhodiščne/najnižje vrednosti pri bolniku), pri tem pa je šlo hkrati za radiološko potrjeno in simptomatsko ali klinično napredovanje bolezni.
In the Phase 3 clinical studies, patients whose baseline ALT or AST were elevated were more likely to experience liver function test elevations than those beginning with normal values.
V kliničnih študijah faze 3 je bila verjetnost za zvišanje vrednosti testov jetrne funkcije večja pri bolnikih, katerih vrednosti ALT ali AST so bile zvišane že v izhodišču, kakor pri tistih bolnikih, ki so imeli v izhodišču normalne vrednosti.
Cardiac disorders common: cardiac failure*, angina pectoris, atrial fibrillation, tachycardia uncommon: other arrhythmias not known: myocardial infarction, QT prolongation (see sections 4.4 and 4.5)
Srčne bolezni pogosti: srčno popuščanje,* angina pektoris, atrijska fibrilacija, tahikardija občasni: druge aritmije neznana: miokardni infarkt, podaljšanje intervala QT (glejte poglavji 4.4. in 4.5)
Musculoskeletal and connective tissue disorders uncommon: myopathy, rhabdomyolysis
Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni: miopatija, rabdomioliza
ZYTIGA in combination with prednisone or prednisolone may increase bone loss.
Jemanje zdravila ZYTIGA skupaj s prednizonom ali prednizolonom lahko zmanjšanje kostne gostote poveča.
Other side effects include:
Drugi možni neželeni učinki:
What ZYTIGA looks like and contents of the pack - ZYTIGA tablets are purple, oval-shaped, film-coated (20 mm long by 10 mm wide) with “AA” written on one side and “500” on the other side.
Izgled zdravila ZYTIGA in vsebina pakiranja - Tablete ZYTIGA so vijolične, ovalne oblike, filmsko obložene tablete (dolge 20 mm in široke 10 mm), “AA” na eni strani in oznako “500” na drugi strani.
This medicinal product also contains more than 1 mmol (or 27.2 mg) sodium per dose of four tablets.
Zdravilo vsebuje tudi več kot 1 mmol (oziroma 27,2 mg) natrija na odmerek (v štirih tabletah).
CYP17 catalyses the conversion of pregnenolone and progesterone into testosterone precursors, DHEA and androstenedione, respectively, by 17α-hydroxylation and cleavage of the C17,20 bond.
CYP17 katalizira pretvorbo pregnenolona in progesterona v dehidroepiandrosteron (DHEA) oziroma androstenedion, ki sta predstopnji testosterona, in sicer s hidroksilacijo na mestu 17α in s cepitvijo vezi na mestih C17,20.
Swallow the tablets whole with water.
Tablete pogoltnite cele z vodo.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this medicine.
Če niste prepričani, ali katera od teh navedb velja za vas, se pred uporabo zdravila posvetujte z zdravnikom ali farmacevtom.
Purple, oval-shaped, film-coated tablets (20 mm long by 10 mm wide), debossed with “AA” on one side and “500” on the other side.
Vijolične, ovalne filmsko obložene tablete (dolge 20 mm in široke 10 mm), z vtisnjeno oznako “AA” na eni strani in “500” na drugi strani.
Administration in patients with renal impairment, including severe renal impairment, does not require dose reduction (see section 4.2).
Pri uporabi pri bolnikih z okvaro ledvic, tudi pri tistih s hudo okvaro ledvic, ni treba zniževati odmerkov (glejte poglavje 4.2).
Use with chemotherapy
Sočasna uporaba kemoterapije